RE: Makes sense!17 Nov 2020 19:01
From Brh Rns on 9th nov
Braveheart also announces that on 5 and 6 November 2020, it sold a total of 120 million ordinary shares in RMS at a weighted average price of 2.6265p per share, realising gross proceeds of approximately £3.15 million. The net funds receivable by Braveheart are primarily intended to fund the COVID-19 test project, as required and assuming it continues to deliver the results necessary to justify continuing the project, being conducted by Paraytec Limited through to a point where it is ready for commercial launch.
Hope that helps.